Exponent initiated with an Overweight at JPMorgan

JPMorgan analyst Tomohiko Sano initiated coverage of Exponent (EXPO) with an Overweight rating and $100 price target representing 35% upside potential. Exponent is a leader in science and engineering consulting, serving over 2,000 clients across 17 primary practices, the analyst tells investors in a research note. The firm says the company is positioned for a “strong rebound,” with its revenue growth projected to accelerate to 9.5% in 2026 and margin expansion as headwinds ease and utilization improves. The stock offers potential upside as Exponent’s fundamentals recover and valuation normalizes, contends JPMorgan.